Compare Genuine Parts Company (GPC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Merck & Co., Inc. — how do they compare? Genuine Parts Company trades at $125 (market cap $16.65B), while Merck & Co., Inc. trades at $127.3 (market cap $305.29B). The key difference: Merck & Co., Inc. is far larger — about 18.3× Genuine Parts Company's market cap, and Genuine Parts Company pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| GPC | MRK | |
|---|---|---|
Market Cap | $16.65B | $305.29B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $129.52 |
52-Week Low | $92.47 | $77.60 |
Enterprise Value | $22.87B | $348.71B |
Dividend Yield | 3.51% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GPC trades at $125.40, up 2.65% with a bullish technical signal. The stock shows mixed fundamentals with a high P/E ratio of 275 but strong gross margins of 36.87%. Recent earnings beat expectations in Q1 2026 after two consecutive misses, with Q2 2026 results expected July 21. Analyst consensus is mixed with 43% buy ratings and a $133 price target, while technical indicators show support at $119-120 and resistance at $122-124.
GPC presents a cautious opportunity with dividend stability but faces profitability challenges. The 70-year dividend growth history provides income appeal, though net margins below 1% and declining cash flow trends warrant monitoring. Upside exists if Q2 earnings beat expectations, but weak profitability and rising debt-to-asset ratios pose significant risks to shareholder value.
MRK's stock trades at $128.08, up 6.02% over the past day, reflecting strong momentum. The technical outlook is bullish based on moving averages, with key support at $121 and resistance at $126. Fundamentally, the company reported $65.01B in 2025 revenue with a net income margin of 13.59%, and recent earnings beats in Q3 2025 and Q4 2025 highlight operational strength. The pending acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, signaling strategic growth initiatives.
The investment outlook for MRK is positive, supported by analyst consensus with a $137.30 price target and 67.57% buy ratings. Key opportunities include robust profitability and pipeline expansion via M&A, while risks involve rising debt levels and competitive pressures in the pharmaceutical sector. Earnings growth and successful integration of acquisitions are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
